Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Residual Cancer Burden (RCB)

The Residual Cancer Burden (RCB) score quantifies the extent of residual disease in the breast and axillary lymph nodes after neoadjuvant chemotherapy.

Evidence-based context for fast calculator use

Purpose:
Residual Cancer Burden score quantifies remaining breast tumor after neoadjuvant chemotherapy to classify pathologic response and guide adjuvant care.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
Primary Tumor Bed Dimension 1, Primary Tumor Bed Dimension 2, Average Cellularity, Number of Positive Lymph Nodes, Diameter of Largest Node Metastasis
Reference:
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422.
HomeResidual Cancer Burden (RCB)
Pin your most used calculators here by clicking the star in the dropdown.

Residual Cancer Burden (RCB)

mm
mm
%
mm

Clinical Context & Background

The Residual Cancer Burden (RCB) score quantifies the extent of residual disease in the breast and axillary lymph nodes after neoadjuvant chemotherapy. It is a continuous variable that correlates strongly with distant relapse-free survival.
Primary Source EvidenceSymmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422.
Formula Logic
RCB = 1.4(finv × dprim)^0.17 + [4(1 - 0.75^LN) × dmet]^0.17

Reference Data

RCB ClassScore RangePrognosis
RCB-00Pathologic Complete Response (pCR)
RCB-I0 - 1.36Minimal Burden (Good Prognosis)
RCB-II1.36 - 3.28Moderate Burden
RCB-III> 3.28Extensive Burden (Poor Prognosis)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Residual Cancer Burden (RCB) when residual Cancer Burden score quantifies remaining breast tumor after neoadjuvant chemotherapy to classify pathologic response and guide adjuvant care.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning RCB-0 through RCB-III.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify Primary Tumor Bed Dimension 1, Primary Tumor Bed Dimension 2, Average Cellularity, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should Residual Cancer Burden (RCB) be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can Residual Cancer Burden (RCB) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.